CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Restasis (cyclosporine ophthalmic emulsion) 0.05% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00986427
NCT00986427Phase 2Completed
CompareCT.gov

Restasis® Ophthalmic Emulsion for the Treatment of Brittle Nails

Julian M. Mackay-Wiggan·interventional·Posted Sep 30, 2009·Updated Aug 20, 2013

In Brief

A Phase 2 clinical trial evaluating Restasis (cyclosporine ophthalmic emulsion) 0.05% and Refresh® Dry Eye therapy for Brittle Nails. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This purpose of this study is to assess the safety and effectiveness of Restasis® ophthalmic emulsion versus emulsion alone( Refresh Dry Eye therapy) both for the treatment of brittle nails and for the enhancement of normal nail growth and texture. The investigators think that daily application of Restasis® to nails and nail beds in patients with brittle nails will enhance nail growth and improve nail texture in both affected and unaffected nails.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrittle Nails
CountriesUnited States
CollaboratorsAllergan

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 30, 2009
Enrollment StartJul 1, 2009
Primary CompletionJul 1, 2010
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.8 years ago

Interventions

Restasis (cyclosporine ophthalmic emulsion) 0.05%drug

cyclosporine ophthalmic emulsion 0.05%

Refresh® Dry Eye therapydrug

Emulsion contains glycerin 1% and polysorbate 80